Evidence map›Paper›PMID 21844885›Full record

Trial reportThe pharmacogenomics journal2012

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.

A K Koutras, A G Antonacopoulou, A G Eleftheraki, F-I Dimitrakopoulos, A Koumarianou, I Varthalitis, F Fostira, J Sgouros, E Briasoulis, E Bournakis and 7 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The pharmacogenomics journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04863768 (Molecular Profiling of Colorectal Cancer), which is not on this map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04863768 unknown statusnot on this map

Molecular Profiling of Colorectal Cancer: A Translational Research Study With a Next Generation Sequencing Panel.

TypeobservationalSponsorHellenic Cooperative Oncology GroupRan2006 to 2022Enrolled300ConditionsColorectal Cancer, Colon Cancer, Colon AdenocarcinomaArmsGene panel
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Review
  12. A Genetic Variant inFrontiers in oncology · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. International journal of molecular sciences · 2019
    Article
  18. Article
  19. Review
  20. Role ofOncotarget · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 1 country.

A K KoutrasDepartment of Medicine, Division of Oncology, University Hospital of Patras, Rion, Greece. angkoutr@otenet.gr
A G Antonacopoulou
A G Eleftheraki
F-I Dimitrakopoulos
A Koumarianou
I Varthalitis
F Fostira
J Sgouros
E Briasoulis
E Bournakis
D Bafaloukos
I Bompolaki
E Galani
K T Kalogeras
D Pectasides
G Fountzilas
H P Kalofonos
General University Hospital of Patras · GRAristotle University of Thessaloniki · GRChania General Hospital ”St. George” · GRMetropolitan Hospital · GRUniversity General Hospital Attikon · GRAlexandra Hospital · GRHellenic Cooperative Oncology Group · GRHospital Agioi Anargyroi · GRNational Centre of Scientific Research "Demokritos" · GRUniversity Hospital of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to evaluate the association of vascular endothelial growth factor (VEGF) genotypes with treatment efficacy in a randomized trial. This study compared two chemotherapy regimens (FOLFIRI versus XELIRI) combined with bevacizumab, as first-line treatment for metastatic colorectal cancer. DNA was extracted from blood samples of 173 patients participating in the trial. Genotyping was performed for selected SNPs (VEGF-1154, +936, -634, -2578 and -1498). All candidate genotypes were evaluated for associations with overall survival (OS), progression-free survival (PFS) and response rate (RR). There were no significant differences with respect to the distribution of genotypes in the treatment groups. The VEGF-1154 GG genotype was more frequent in patients not responding to treatment compared with responders (65.5 versus 39.8%, P = 0.032). Furthermore, the VEGF-1154 GG genotype was associated with inferior median OS compared with GA (hazards ratio = 1.68; 95% confidence interval: 1.10-2.57; P = 0.016) or with the alternative genotypes (GA and AA) combined (hazards ratio = 1.62; 95% confidence interval: 1.09-2.40; P = 0.017). In multivariate analysis, the VEGF-1154 GG genotype remained a significant adverse factor for OS. Our results support the potential predictive ability of VEGF genotypes in patients with metastatic colorectal cancer receiving irinotecan-based chemotherapy plus bevacizumab, in terms of RR and OS. However, current results should be validated prospectively, in larger cohorts.

Indexed as

Polymorphism, Single NucleotideAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCamptothecinColorectal NeoplasmsFemaleGenotypeHumansIrinotecanLinkage DisequilibriumMaleMiddle AgedAntibodies, Monoclonal, HumanizedBevacizumabCamptothecinIrinotecanVascular Endothelial Growth Factor A

Identifiers

PMID21844885
OpenAlexW1963832292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.